Abeona Therapeutics (NASDAQ:ABEO) Issues Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Abeona Therapeutics (NASDAQ:ABEO) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.19, Zacks reports.

Abeona Therapeutics Price Performance

ABEO opened at $5.14 on Friday. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics has a 1 year low of $3.05 and a 1 year high of $8.45. The stock has a fifty day moving average price of $5.45 and a 200 day moving average price of $5.83. The stock has a market cap of $223.44 million, a price-to-earnings ratio of -1.91 and a beta of 1.79.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a research note on Wednesday, February 19th. Oppenheimer assumed coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 target price on the stock. Finally, StockNews.com downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 22nd. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Abeona Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $17.50.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.